Clinical Biofilm Group

   
Associate professor, PhD,
senior researcher
Thomas Emil Andersen
MD, PhD, Department specialist
Kasper Klein
 MD, PhD, Department specialist
Rune Micha Pedersen
     
MSc., PhD, postdoc
Rasmus Birkholm Grønnemose
MD, PhD student
Kristian Stærk
 Biomedical laboratory scientist
Karina Rosenlund
     
Bachelor student 
Ditte Tornby
 Bachelor student 
Anne Sofie Løgstrup Henriksen
 


Members

Thomas Emil Andersen, Assoc. professor, PhD

Rune Micha Pedersen, MD, PhD, Department Specialist

Kasper Klein, MD, PhD, Department Specialist

Rasmus Birkholm Grønnemose, MSc, PhD, postdoc

Kristian Stærk, MD, PhD student

Karina Rosenlund, Biomedical Laboratory Scientist

Ditte Tornby, BSc student

Anne Sofie Løgstrup Henriksen, BSc student

The Clinical Biofilm Group is member of the SDU Centre for Translational Microbiology and the OUH Frontline Centre For Renal Diseases, Uremia and Transplantation (CENTRA).

 

Research focus

Biofilm-related infections continue to be a major problem at hospitals. Bacteria and fungi are efficient colonizers of implants and indwelling medical devices, which leads to failure of device function and compromised patient treatment. In addition, pathogenic organisms may use biofilm growth as a means of surviving host response in the body’s inner cavities, facilitating invasion and systemic infection.

In the Clinical Biofilm Group at the Dept. of Clinical Microbiology, Odense University Hospital, our research is based on  innovative in vitro infection models intended to reproduce keys steps of pathogenesis. Liquid flow-assisted infection models are utilized to create accurate physiological hydrodynamic conditions and to obtain a controlled physicochemical micromilieu that simulates specific infection sites.

To assist the in vitro model research, the group has at its disposal various animal infection models, developed in collaboration with local hospital departments. The combined experimental platform enables detailed studies of infection pathogenesis and functions as a test platform for the development of novel antimicrobials and biocompatible device materials. 

Current projects

 

New treatment against Clostridium difficile infection

This project aims to elucidate the pathogenesis associated with Clostridium difficile intestinal infection. This organism is a major problem at hospitals worldwide, due to its resistance towards many antibiotics. Patients treated with antibiotics often lose their normal intestinal flora, leaving ideal conditions for C. diff. As a consequence, patients may become chronically infected with C. diff., resulting in significant morbidity among these patients. Using the in vitro intestinal infection models developed by the Clinical Biofilm Group, the colonization mechanisms  by C. diff is investigated and novel treatment regimens are developed and tested. The project is funded by the Mica Foundation.

 

Unique IPN technology Prevents Device Thrombosis

An interdisciplinary project cooperation with partners from academia and the industry. Project partners include the thrombosis research unit, Hospital of Southwest Jutland, Dept. of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Dept. of Cancer and Inflammation, University of Southern Denmark, Biomodics Aps, and Niels Clauson-Kaas A/S. The project is funded by The Innovation Fund Denmark and aims to develop a novel hybrid polymer material that improves blood compatibility and infection resistance of blood-contact devices.

 

Urinary tract infections in patients with neurogenic bladder: Elucidation of pathogenesis for improved diagnosis and treatment

A project conducted in cooperation with the Dept. of Urology, Odense University Hospital, the Thrombosis Research Unit, Hospital of Southwest Jutland and the Danish medico company Coloplast A/S. The project is supported by the Region of Southern Denmark and Coloplast A/S and aims to elucidate urinary tract infection pathogenesis in high-risk patient groups.

 

pURIcat

Project cooperation with Biomodics ApS (DK) and Venair Iberica SA (ES). Funded by the Horizon 2020 Eurostars Programme. In the project, a novel anti-infection balloon urinary catheter is developed.

Read news article about pURIcat here (in Danish).

 

Next generation in vitro bloodstream infection model

Funded by the Danish Agricultural Agency. In the project, a novel bloodstream infection model is developed which accurately reproduces the physiologic conditions in the bloodstream. The model enables detailed studies of the interplay between bloodstream pathogens and the host, and provides a platform for testing of blood-compatible device materials. Since the model recapitulates several aspects of the living organism, it is expected to provide a general concept that can help reduce the need for animal testing.


BacSens
A cross-disciplinary project in which the Clinical Biofilm Group collaborates with the Danish Fundamental Metrology Institute (DK), BacAlert IVS (DK) and art photonics GmbH (DE) with the common goal of developing next generation technology for fast identification of pathogenic bacteria.
The project is funded by the European Union EUREKA programme.

Read BacSens news article in "Ingeniøren" here (in Danish).

See BacSens press release here (in Danish).

 

Current PhD-projects

Kristian Stærk

Elucidation of the role of Escherichia coli type-1 fimbriae in persistent cystitis and assessment of Low-Intensity Extracorporeal Shockwave Treatment to potentiate antibiotic susceptibility.

   

Recently defended PhD-projects

Kasper Klein, MD:

Treatment of device-associated infections with novel antimicrobial compounds: the effect of thioridazine, plectasin and novicidin on bacterial adhesion and biofilm formation.

 

Rasmus Birkholm Grønnemose, MSc:

Catheter-related Thrombosis: Pathogenesis and Prevention.

 

Rune Micha Pedersen, MD:

Shiga toxin-producing Escherichia coli: formation of biofilm, cellular destruction and activation of complement - an in vitro study.

 

Selected papers

Nielsen TK, Petersen NA, Stærk K, Grønnemose RB, Palarasah Y, Nielsen LF, Kolmos HJ, Andersen TE and Lund L. A Porcine Model for Urinary Tract Infection. Front. Microbiol. 2019. 10:2564. doi: 10.3389/fmicb.2019.02564

 

Pedersen RM, Grønnemose RB, Stærk K, Asferg CA, Andersen TB, Kolmos HJ, Møller-Jensen J, Andersen TE*. A method for quantification of epithelium colonization capacity by pathogenic bacteria. Front. Cell. Infect. Microbiol. 2018;8:16. doi: 10.3389/fcimb.2018.00016.

 

Grønnemose RB, Saederup KL, Kolmos HJ, Hansen SWK, Asferg CA, Rasmussen KJ, Palarasah Y, Andersen TE*. A novel in vitro model for hematogenous spreading of S. aureus device biofilms demonstrating clumping dispersal as an advantageous dissemination mechanism. Cell. Microbiol. 2017 Dec;19(12). doi: 10.1111/cmi.12785.

 

Klein K, Grønnemose BG, Alm M, Brinch KS, Kolmos HJ, Andersen TE*: Slow release of Plectasin NZ2114 from a hybrid silicone-hydrogel material effectively prevents Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 2017;61: e00604-17.

 

Stenger M, Behr-Rasmussen C, Klein K, Grønnemose RB, Andersen TE, Klitgaard JK, Kolmos HJ, Lindholt JS. Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity. PLoS One. 2017 Mar 9;12(3):e0173362. doi: 10.1371.

 

Stenger M, Klein K, Grønnemose BG, Klitgaard J, Kolmos HJ, Lindholt JS, Alm M, Thomsen P, Andersen TE*. Co-release of dicloxacillin and thioridazine from catheter material containing an interpenetrating polymer network for inhibiting device-associated Staphylococcus aureus infection. J. Control. Release. 2016;241:125-134

 

Khandige S, Asferg CA, Rasmussen KJ, Larsen MJ, Overgaard M, Andersen TE*, Møller-Jensen J*. DamX controls reversible cell morphology-switching in uropathogenic Escherichia coli. mBio. 2016;7:e00642-16.

 

Stærk K, Khandige K, Kolmos HJ, Møller-Jensen J, Andersen TE*. Uropathogenic Escherichia coli express type-1 fimbriae only in sessile populations under physiological growth conditions. J. Infect. Dis. 2016;213:386-94.

 

Citterio L, Franzyk H, Palarasah Y, Andersen TE, Mateiu RV, Gram L. Improved in vitro evaluation of novel antimicrobials: potential synergy between human plasma and antibacterial peptidomimetics, AMPs and antibiotics against human pathogenic bacteria. Res. Microbiol. 2016;167:72-82.

 

Klein K, Palarasah Y, Kolmos HJ, Møller-Jensen J, Andersen TE*. Quantification of filamentation by uropathogenic Escherichia coli during experimental bladder cell infection by using semi-automated image analysis. J. Microbiol. Methods. 2015;109:110-116